The association between breastmilk group B Streptococcal capsular antibody levels and late-onset disease in young infants.
Animal-model studies demonstrated less group B streptococcal (GBS) invasive disease and gastrointestinal colonization after enteral administration of serotype-specific capsular antibody. There is however a paucity of information on the association of breastmilk GBS serotype-specific capsular antibody and risk for invasive disease in infants. The aim of this study was to explore the association between natural secretory IgA (sIgA) capsular antibody in breastmilk, and the occurrence of late-onset disease (LOD) in young infants. A matched case-control study was undertaken in infants <3months of age in Johannesburg, South Africa. Breastmilk samples were collected on cases and controls matched for gestational age, maternal age and HIV-status at time of enrolment. Capsular serotype Ia, Ib, III and V sIgA antibody concentrations were measured using the fluorescence based micro-bead immunosorbent assay. Breastmilk samples were available for 31 LOD (8 serotype Ia and 23 serotype III), 10 serotype Ia and 11 serotype III recto-vaginally colonized matched controls, and 84 and 105 non-colonized matched controls. Using a Bayesian model to estimate the probability of disease, there was a 90% reduction in the risk of developing serotype Ia and III LOD with sIgA concentrations ≥0.14 µg/mL and ≥2.52 µg/mL, respectively. Breastmilk sIgA capsular antibody was associated with lower risk for LOD in young infants. The ability of GBS polysaccharide-protein conjugate vaccines currently under development to induce sIgA responses warrant investigation as a potential mediator of protection against LOD.